P/B
230,6
Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
$5.7B
Market Cap • 9/29/2026
2011
(15 years)
Founded
2003
(23 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
9,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,3
EPS
—
Market Cap
Market Cap
5,7B
EV
5,8B
EV/Revenue
9,8
EV/EBITDA
-142,9
EV/EBIT
-142,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
98,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
38,4%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
65,4%
% PPE
1,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
23,7%
CAGR Op. Income 5Y
-28,8%
CAGR Net Income 5Y
-22,2%
CAGR EPS 5Y
-36,4%
CAGR OCF 5Y
-100%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
4
Quick Ratio
3,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!